发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Crosstalk of T cells within the ovarian cancer microenvironment. 卵巢癌微环境中 T 细胞的相互影响。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-09-27 DOI: 10.1016/j.trecan.2024.09.001
Bovannak S Chap, Nicolas Rayroux, Alizée J Grimm, Eleonora Ghisoni, Denarda Dangaj Laniti
{"title":"Crosstalk of T cells within the ovarian cancer microenvironment.","authors":"Bovannak S Chap, Nicolas Rayroux, Alizée J Grimm, Eleonora Ghisoni, Denarda Dangaj Laniti","doi":"10.1016/j.trecan.2024.09.001","DOIUrl":"10.1016/j.trecan.2024.09.001","url":null,"abstract":"<p><p>Ovarian cancer (OC) represents ecosystems of highly diverse tumor microenvironments (TMEs). The presence of tumor-infiltrating lymphocytes (TILs) is linked to enhanced immune responses and long-term survival. In this review we present emerging evidence suggesting that cellular crosstalk tightly regulates the distribution of TILs within the TME, underscoring the need to better understand key cellular networks that promote or impede T cell infiltration in OC. We also capture the emergent methodologies and computational techniques that enable the dissection of cell-cell crosstalk. Finally, we present innovative ex vivo TME models that can be leveraged to map and perturb cellular communications to enhance T cell infiltration and immune reactivity.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1116-1130"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering growth factor ligands and receptors for therapeutic innovation. 对生长因子配体和受体进行工程设计，以实现治疗创新。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1016/j.trecan.2024.09.006
Xinran An, Justin Paoloni, Yuseong Oh, Jamie B Spangler
{"title":"Engineering growth factor ligands and receptors for therapeutic innovation.","authors":"Xinran An, Justin Paoloni, Yuseong Oh, Jamie B Spangler","doi":"10.1016/j.trecan.2024.09.006","DOIUrl":"10.1016/j.trecan.2024.09.006","url":null,"abstract":"<p><p>Growth factors signal through engagement and activation of their respective cell surface receptors to choreograph an array of cellular functions, including proliferation, growth, repair, migration, differentiation, and survival. Because of their vital role in determining cell fate and maintaining homeostasis, dysregulation of growth factor pathways leads to the development and/or progression of disease, particularly in the context of cancer. Exciting advances in protein engineering technologies have enabled innovative strategies to redesign naturally occurring growth factor ligands and receptors as targeted therapeutics. We review growth factor protein engineering efforts, including affinity modulation, molecular fusion, the design of decoy receptors, dual specificity constructs, and vaccines. Collectively, these approaches are catapulting next-generation drugs to treat cancer and a host of other conditions.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1131-1146"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications. 小儿胶质瘤的表观遗传学重编程：从分子机制到治疗意义。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1016/j.trecan.2024.09.007
Santiago Haase, Stephen Carney, Maria Luisa Varela, Devarshi Mukherji, Ziwen Zhu, Yingxiang Li, Felipe J Nuñez, Pedro R Lowenstein, Maria G Castro
{"title":"Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications.","authors":"Santiago Haase, Stephen Carney, Maria Luisa Varela, Devarshi Mukherji, Ziwen Zhu, Yingxiang Li, Felipe J Nuñez, Pedro R Lowenstein, Maria G Castro","doi":"10.1016/j.trecan.2024.09.007","DOIUrl":"10.1016/j.trecan.2024.09.007","url":null,"abstract":"<p><p>Brain tumors in children and adults differ greatly in patient outcomes and responses to radiotherapy and chemotherapy. Moreover, the prevalence of recurrent mutations in histones and chromatin regulatory proteins in pediatric and young adult gliomas suggests that the chromatin landscape is rewired to support oncogenic programs. These early somatic mutations dysregulate widespread genomic loci by altering the distribution of histone post-translational modifications (PTMs) and, in consequence, causing changes in chromatin accessibility and in the histone code, leading to gene transcriptional changes. We review how distinct chromatin imbalances in glioma subtypes impact on oncogenic features such as cellular fate, proliferation, immune landscape, and radio resistance. Understanding these mechanisms of epigenetic dysregulation carries substantial implications for advancing targeted epigenetic therapies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1147-1160"},"PeriodicalIF":14.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic control of immunoevasion in cancer stem cells. 癌症干细胞免疫逃逸的表观遗传学控制。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-09-06 DOI: 10.1016/j.trecan.2024.08.004
Claudia Galassi, Manel Esteller, Ilio Vitale, Lorenzo Galluzzi
{"title":"Epigenetic control of immunoevasion in cancer stem cells.","authors":"Claudia Galassi, Manel Esteller, Ilio Vitale, Lorenzo Galluzzi","doi":"10.1016/j.trecan.2024.08.004","DOIUrl":"10.1016/j.trecan.2024.08.004","url":null,"abstract":"<p><p>Cancer stem cells (CSCs) are a poorly differentiated population of malignant cells that (at least in some neoplasms) is responsible for tumor progression, resistance to therapy, and disease relapse. According to a widely accepted model, all stages of cancer progression involve the ability of neoplastic cells to evade recognition or elimination by the host immune system. In line with this notion, CSCs are not only able to cope with environmental and therapy-elicited stress better than their more differentiated counterparts but also appear to better evade tumor-targeting immune responses. We summarize epigenetic modifications of DNA and histones through which CSCs evade immune recognition or elimination, and propose that such alterations constitute promising therapeutic targets to increase the sensitivity of some malignancies to immunotherapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1052-1071"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms governing lineage plasticity and metabolic reprogramming in cancer. 癌症的血统可塑性和代谢重编程机制。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-08-31 DOI: 10.1016/j.trecan.2024.08.001
Lillian M Perez, Smrruthi V Venugopal, Anna St Martin, Stephen J Freedland, Dolores Di Vizio, Michael R Freeman
{"title":"Mechanisms governing lineage plasticity and metabolic reprogramming in cancer.","authors":"Lillian M Perez, Smrruthi V Venugopal, Anna St Martin, Stephen J Freedland, Dolores Di Vizio, Michael R Freeman","doi":"10.1016/j.trecan.2024.08.001","DOIUrl":"10.1016/j.trecan.2024.08.001","url":null,"abstract":"<p><p>Dynamic alterations in cellular phenotypes during cancer progression are attributed to a phenomenon known as 'lineage plasticity'. This process is associated with therapeutic resistance and involves concurrent shifts in metabolic states that facilitate adaptation to various stressors inherent in malignant growth. Certain metabolites also serve as synthetic reservoirs for chromatin modification, thus linking metabolic states with epigenetic regulation. There remains a critical need to understand the mechanisms that converge on lineage plasticity and metabolic reprogramming to prevent the emergence of lethal disease. This review attempts to offer an overview of our current understanding of the interplay between metabolic reprogramming and lineage plasticity in the context of cancer, highlighting the intersecting drivers of cancer hallmarks, with an emphasis on solid tumors.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1009-1022"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in cancer imaging. 癌症成像趋势。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1016/j.trecan.2024.08.006
Xinyuan Zhou, Binyu Shi, Gang Huang, Jianjun Liu, Weijun Wei
{"title":"Trends in cancer imaging.","authors":"Xinyuan Zhou, Binyu Shi, Gang Huang, Jianjun Liu, Weijun Wei","doi":"10.1016/j.trecan.2024.08.006","DOIUrl":"10.1016/j.trecan.2024.08.006","url":null,"abstract":"<p><p>Molecular imaging of cancer is a collaborative endeavor, uniting scientists and physicians from diverse fields. Such collaboration is actively developing and translating cutting-edge molecular imaging approaches to enhance the diagnostic landscape of human malignancies. The advent of positron emission tomography (PET) and PET imaging tracers has realized non-invasive target annotation and tumor characterization at the molecular level. In surgical procedures, novel imaging techniques, such as fluorescence or Cherenkov luminescence, help identify tumors and enhance surgical precision. Simultaneously, progress in imaging equipment, innovative algorithms, and artificial intelligence has opened avenues for next-generation cancer screening and imaging, augmenting the efficiency and accuracy of cancer diagnosis. In this review, we provide a panorama of molecular cancer imaging and ongoing developments in the field.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1023-1037"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of atypical B cells in breast cancer. 乳腺癌非典型 B 细胞的预后价值。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-01 DOI: 10.1016/j.trecan.2024.09.009
Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué
{"title":"Prognostic value of atypical B cells in breast cancer.","authors":"Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué","doi":"10.1016/j.trecan.2024.09.009","DOIUrl":"10.1016/j.trecan.2024.09.009","url":null,"abstract":"<p><p>The impact of tumor-infiltrating B cells on breast cancer (BRCA) outcomes remains poorly understood. Recent findings from Yang et al. identify an atypical, clonally expanded population of activated Fc receptor-like 4 (FCRL4)<sup>+</sup> B cells that is associated with improved overall survival in patients affected by various tumor types, including BRCA.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"990-991"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accessing the vasculature in cancer: revising an old hallmark. 进入癌症血管：重新审视古老的标志。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI: 10.1016/j.trecan.2024.08.003
Adrian L Harris, David J Kerr, Francesco Pezzella, Domenico Ribatti
{"title":"Accessing the vasculature in cancer: revising an old hallmark.","authors":"Adrian L Harris, David J Kerr, Francesco Pezzella, Domenico Ribatti","doi":"10.1016/j.trecan.2024.08.003","DOIUrl":"10.1016/j.trecan.2024.08.003","url":null,"abstract":"<p><p>The classic cancer hallmark, inducing angiogenesis, was born out of the long-held notion that tumours could grow only if new vessels were formed. The attempts, based on this premise, to therapeutically restrain angiogenesis in hopes of controlling tumour growth have been less effective than expected. This is partly because primary and metastatic tumours can grow without angiogenesis. The discovery of nonangiogenic cancers and the mechanisms they use to exploit normal vessels, called 'vessel co-option,' has opened a new field in cancer biology. Consequently, the cancer hallmark, 'inducing angiogenesis,' has been modified to 'inducing or accessing vasculature.'</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1038-1051"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence. 愈合时间：抑制纤维化可预防胶质母细胞瘤复发。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI: 10.1016/j.trecan.2024.09.008
Dhanashree Mundhe, Neta Erez
{"title":"Time to heal: inhibiting fibrosis prevents glioblastoma recurrence.","authors":"Dhanashree Mundhe, Neta Erez","doi":"10.1016/j.trecan.2024.09.008","DOIUrl":"10.1016/j.trecan.2024.09.008","url":null,"abstract":"<p><p>New findings by Watson et al. demonstrate that therapy-induced inflammation and fibrosis potentiate glioblastoma recurrence. Post-treatment fibrotic niches shielded surviving tumor cells from immune surveillance, supported their persistence in a dormant state, and enabled rebound growth. Timely inhibition of inflammation and scarring attenuated recurrence, encouraging the use of new combinatorial approaches in glioblastoma therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"987-989"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. 小细胞肺癌特征分析：亚型、脆弱性和可塑性的最新综述。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-08-19 DOI: 10.1016/j.trecan.2024.07.008
Esther Redin, Álvaro Quintanal-Villalonga, Charles M Rudin
{"title":"Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity.","authors":"Esther Redin, Álvaro Quintanal-Villalonga, Charles M Rudin","doi":"10.1016/j.trecan.2024.07.008","DOIUrl":"10.1016/j.trecan.2024.07.008","url":null,"abstract":"<p><p>Small cell lung cancer (SCLC) is a devastating disease with high proliferative and metastatic capacity. SCLC has been classified into molecular subtypes based on differential expression of lineage-defining transcription factors. Recent studies have proposed new subtypes that are based on both tumor-intrinsic and -extrinsic factors. SCLC demonstrates substantial intratumoral subtype heterogeneity characterized by highly plastic transcriptional states, indicating that the initially dominant subtype can shift during disease progression and in association with resistance to therapy. Strategies to promote or constrain plasticity and cell fate transitions have nominated novel targets that could prompt the development of more durably effective therapies for patients with SCLC. In this review, we describe the latest advances in SCLC subtype classification and their biological and clinical implications.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"935-946"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信